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Abstract
The tripartite efflux system AcrA/AcrB/TolC is the main
pump in Escherichia coli for the efflux of multiple anti-
biotics, dyes, bile salts and detergents. The inner
membrane component AcrB is central to substrate rec-
ognition and energy transduction and acts as a proton/
drug antiporter. Recent structural studies show that
homotrimeric AcrB can adopt different monomer confor-
mations representing consecutive states in an allosteric
functional rotation transport cycle. The conformational
changes create an alternate access drug transport tunnel
including a hydrophobic substrate binding pocket in one
of the cycle intermediates.
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Introduction
Resistance of bacteria towards antibiotics is known to be
evoked by at least three different mechanisms: (i) target
modification we.g., resistance against macrolides medi-
ated by methylation of the ribosome (Skinner et al., 1983;
Zalacain and Cundliffe, 1989, 1990) or resistance against
fluoroquinolones by mutations in DNA gyrase (Yoshida et
al., 1990; Hooper, 1995)x; (ii) antibiotic modification (e.g.,
hydrolysis of b-lactam ring by b-lactamase; Thomson
and Smith Moland, 2000) or phosphorylation, adenylation
or acetylation of aminoglycosides (Wright, 1999); and
(iii) reduced accumulation of antibiotics in the target
compartments (periplasm, cytoplasm) through suppres-
sion of porin synthesis (Hancock and Brinkman, 2002)
and/or overproduction of efflux pumps (Nikaido, 1998,
2009; Lomovskaya et al., 1999; Li and Nikaido, 2004;
Lomovskaya and Totrov, 2005; Nikaido and Takatsuka,
2008).
Resistance conferred by antibiotic and target modifi-
cation is often restricted to a single class of antibiotics
or even a single compound. In contrast, multidrug resis-
tance (MDR) transporters enable the bacteria to efflux a
broad range of substances and hence confer simulta-
neous resistance to unrelated compounds. The central
role of MDR transporters as a primary line of defense
and, intriguingly, as mediators for the acquisition of other
resistance mechanisms have been shown in several
cases (Lomovskaya et al., 1999; Mazzariol et al., 2000;
Mahamoud et al., 2007).
Proteins of the Resistance-Nodulation-Division (RND)
superfamily (TC2.A.6) are ubiquitous in all phyla. In
prokaryotes, their main physiological function seems to
be associated with the extrusion of noxious substrates,
with notable exceptions such as the secretory accessory
proteins SecDF (Gardel et al., 1987; Pogliano and Beck-
with, 1994), lipid exporter MmpL7 (Camacho et al., 2001;
Domenech et al., 2005) and the putative lipooligosaccha-
ride nodulation factor exporter NolG (Baev et al., 1991).
In Eukarya, however, the functionally characterized RND
proteins seem to be involved in lipid homeostasis (Davies
et al., 2000; Davies and Ioannou, 2000; Sleat et al., 2004;
Infante et al., 2008a,b) and cell morphogenesis (Taipale
et al., 2002; Nakano et al., 2004). As phylogenetic anal-
yses suggest, energization via the proton (or sodium ion)
motive force might be a common feature for all RND
proteins (Saier and Paulsen, 2001).
Resistance nodulation division (RND) efflux
pump AcrB
Proteobacterial members of the RND superfamily are
located in the inner membrane. They typically assemble
with two accessory proteins, a membrane fusion protein
(MFP; TC8.A.1) and an outer membrane factor (OMF;
TC1.B.17). The so-formed tripartite MFP/RND/OMF
complex spans the inner membrane, the periplasm as
well as the outer membrane of the Gram-negative bac-
terium. Most extensively studied examples of these three
component systems are MexA/MexB/OprM of Pseudo-
monas aeruginosa or AcrA/AcrB/TolC of Escherichia coli
(Figure 1A). Both outer membrane and tripartite efflux
pumps are considered to be the main barrier for drugs
on their way to the inside of the bacterial cell (Plesiat and
Nikaido, 1992; Nikaido, 2003, 2009). It is this combina-
tion of the intrinsic impermeability of the outer
membrane, reduction of the number of outer membrane
pores and upregulation of multidrug efflux pumps which
enables effective synergistic drug resistance (Nikaido,
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Figure 1 Schematic drawing of the tripartite multidrug efflux
system AcrAB-TolC of Gram-negative E. coli and AcrB structural
features.
(A) The inner membrane component AcrB (RND component)
accounts for substrate recognition/selection and energy trans-
duction. Drugs might be captured from the outer leaflet of the
inner membrane and are extruded in a coupled exchange with
protons. The TolC channel (OMF component) mediates the exit
through the outer membrane and connects to AcrB via a long
periplasmic conduit. AcrA (MFP component) connects AcrB and
TolC. The presence of all three components is essential for the
MDR phenotype. (B) Topological view of the transmembrane
(TM) domain perpendicular to the membrane plane. TM4 and
TM10 are surrounded by the other 10 TM helices. The TM
domains of the three monomers confine a large central cavity.
(C) Side view of trimeric AcrB. A central pore located in the por-
ter domain separates a funnel-like structure in the TolC-docking
domain from the central cavity located in the TM domain. The
central pore, however, does not appear to allow direct passage
of drugs. The trimeric state of AcrB is mainly stabilized by the
intermonomer connecting loops. (D) Top view of the porter
domain with its subdomains PN1, PN2, PC1 and PC2 perpen-
dicular to the membrane plane. The central pore is formed by
three a-helices, donated by the PN1 subdomains of each AcrB
monomer. A cleft is apparent between the PC1 and PC2
subdomains of each monomer.
1996). Strikingly, dysfunction of only one component of
the tripartite system results in a complete drug-sensitive
phenotype.
RND proteins, such as MexB (Mex: multiple efflux) and
AcrB (Acr: acriflavine resistance), represent the energy
module and the substrate specificity determinant of the
tripartite RND/MFP/OMF efflux system. The substrate
variety of MexB or AcrB, compared to the many other
MDR proteins, is staggering. It includes dyes, bile salts,
organic solvents and antibiotics of different chemical
classes; molecules that are anionic, cationic, zwitterionic,
aromatic or just aliphatic; chemicals of bulky or planar
geometry. However, since export of membrane lipids and
co-factors, such as flavins, is expected to be detrimental
for bacterial cells, additional criteria to discriminate
between noxious compounds and vital cell constituents
must exist, a matter of ongoing research. Like most
proteobacterial RND proteins, AcrB consists of 12 trans-
membrane (TM) a-helices and two extensive periplasmic
loops which account for approximately half of the 1049
amino acids of the protein. The loops connect TM1 with
TM2 and TM7 with TM8, respectively. The topology of
the TM domain – five-plus-one-TM helices, repeated
twice – is also referred to as RND signature (Ioannou,
2001). The repetition of the motif suggests that RND
transporters arose as a result of an intragenic tandem
duplication event.
It appears that the substrate specificity determination
is residing in the periplasmic loops, which was shown
through the design of chimeric proteins. Specifically, the
two extracellular loops of the Escherichia coli aminogly-
coside exporter AcrD were replaced by the periplasmic
loops of AcrB (Elkins and Nikaido, 2002). The resulting
transporter exhibited a resistance pattern that was typi-
cal for AcrB. Conversely, when the periplasmic loops of
AcrB were replaced by the corresponding domains of
AcrD, the chimeric protein lost the ability to confer resis-
tance towards substrates of AcrB, but the resistance
towards aminoglycosides was enhanced. Domain swap-
ping experiments between MexB and MexY led to similar
results (Eda et al., 2003). Here, the periplasmic loops of
MexB were combined with the TM domain of MexY.
Again, the resulting protein conferred resistance towards
typical MexB substrates, while the cells were susceptible
towards MexY specific drugs. Additional evidence on the
role of the periplasmic domain in substrate specificity
determination came from a study where six single site
mutations causing altered substrate specificity were all
found to be located on the extracellular loops (Mao et al.,
2002). Crystallographic studies provided further insights
on the role of the periplasmic loops in substrate recog-
nition and transport (Murakami et al., 2006; Seeger et al.,
2006; Sennhauser et al., 2007).
Structure of AcrB
The first AcrB structure (Murakami et al., 2002) was
based on 3.5 A˚ X-ray diffraction data from crystals con-
taining one unliganded AcrB monomer in the asymmetric
unit and for which the trimer is generated by exact crys-
tallographic symmetry. Each monomer contains a TM
domain with 12 TM helices which form a bundle with two
central helices (TM4 and TM10) in its topological core.
On these central a-helices, three titratable residues,
Asp407, Asp408 and Lys940, were found to be essential
for protein function (Guan and Nakae, 2001; Su et al.,
2006; Takatsuka and Nikaido, 2006; see Figure 1B).
The periplasmic part – formed by the periplasmic loops
described above – extends 70 A˚ into the periplasm. It
can be further divided into a TolC docking domain which
is most distal from the membrane plane and a porter
domain, formerly known as pore domain (Figure 1C).
The TolC-docking domain is the expected interaction
site of the outer membrane channel TolC (Tikhonova and
Zgurskaya, 2004; Tamura et al., 2005; Bavro et al., 2008;
Pietras et al., 2008). The TolC docking domain of each
monomer furthermore exhibits a hairpin-like loop that
protrudes into the neighboring monomer, which appears
Multidrug efflux pump AcrB 695
Article in press - uncorrected proof
Figure 2 Tunnels in the porter domain of trimeric AcrB peristaltic drug efflux pump.
The AcrB monomers are presented in blue (loose), yellow (tight) and red (open). The tunnels are highlighted as green surfaces in a
ribbon model of the AcrB trimer and might function as transport paths of drugs. Tunnel 1 might serve as entrance for drugs from
the outer leaflet of the inner membrane towards the hydrophobic substrate binding pocket. Tunnel 2 might serve as an alternative
entrance for substrates entering via the periplasm or as an exit duct for non-substrates. Tunnel 3 in the open monomer is the exit
pathway for substrates towards TolC and the outside medium. Inset: in the T monomer (yellow), a hydrophobic pocket is defined by
phenylalanine, valine, isoleucine and tyrosine side chains at the PN2/PC1 interface. Bound minocycline is depicted with the observed
electron density in a 2Fo-Fc electron density map contoured 1 s (T. Eicher, M. Seeger, K.M. Pos and colleagues, unpublished data).
Panels (A) and (B) represent in each case a one-third conversion of a full L™T™O™L cycle wadapted from Pos (2009) and modifiedx.
to be the main stabilizing factor for the trimeric AcrB
complex.
The porter domain is divided into subdomains PN1,
PN2, PC1 and PC2, which are coupled by sequential
proximity (PN1–PN2, PC1–PC2) or by sharing b-strands
to form common b-sheets (PN2–PC1, PC2–PN1; see
Figure 1D). The PN1 subdomains are located in the
center of the trimer, surrounded by the PN2, PC1 and
PC2 subdomains towards the periphery. A cleft is appar-
ent between the PC1 and PC2 subdomains, which is
approximately perpendicular to the membrane plane. In
the center of the trimer, the TolC docking domain exhibits
a funnel-like structure narrowing to a central pore,
defined by a-helices (designated pore helices) of the PN1
subdomains of each monomer. This pore has a small
diameter and therefore does not allow drug passage in
this conformation. Towards the membrane plane, the
central pore leads to a central cavity and further to a
30–35 A˚ wide, presumably lipid-filled TM hole defined by
the ring-like arrangement of the TM helices of the trimer.
Three vestibules at the monomer interface located just
above the membrane plane lead towards the central cav-
ity. It is postulated that substrate might access the cen-
tral cavity via these vestibules (Murakami et al., 2002).
Indeed, there have been several reports on AcrB/sub-
strate co-crystals with positive densities in the electron
density maps derived from (symmetric) R32 crystals that
have been interpreted as substrate molecules bound to
the inner wall of the AcrB central cavity (Yu et al.,
2003a,b, 2005; Pos et al., 2004; Tornroth-Horsefield et
al., 2007; see Figure 1B, C).
In 2006 and 2007, three groups independently pub-
lished an asymmetric structure of AcrB grown in the
monoclinic space group C2 (2.8–2.9 A˚; Murakami et al.,
2006; Seeger et al., 2006), triclinic space group P1 (3.0
A˚; Seeger et al., 2006) and an AcrB structure including
bound designed ankyrin repeat proteins (DARPins) grown
in orthorhombic space group P212121 (2.5 A˚; Sennhauser
et al., 2007). The DARPin bound AcrB structure was
almost identical with the AcrB structures crystallized
without binder with root mean square deviation (rmsd) of
the superimposed trimeric structures F1 A˚. The DARPin
molecules only bind to the loose and the tight conform-
ers, resulting in a ratio of two DARPin molecules per AcrB
trimer. This stoichiometry was verified by sedimentation
velocity experiments, suggesting that in solution and
probably also in vivo AcrB adopts mainly the asymmetric
conformation (Sennhauser et al., 2007).
Within the asymmetric AcrB trimer, each monomer has
a different conformation denoted as loose, tight and open
(access, binding and extrusion, respectively; Murakami et
al., 2006; Seeger et al., 2006), while the loose state is
closest to the conformation of the monomers in the
symmetric structure (Murakami et al., 2002). Although the
pore helices are differently oriented in the asymmetric
structure as compared to the symmetric structure, the
pore diameter is similar and hence there does not appear
to be a substrate export pathway through the pore.
Instead, conformer specific cavities and tunnels could be
identified in the porter domain (Murakami et al., 2006;
Seeger et al., 2006; Sennhauser et al., 2007; see Figure
2). In the loose conformer, a tunnel (tunnel 2) starts in the
PC1/PC2 subdomain cleft approximately 15 A˚ above the
membrane plane and protrudes in the direction of the
pore. In the tight conformer, an additional tunnel (tunnel
1) with an entrance situated in a groove formed by TM8
and TM9 at the height of the membrane plane is appar-
ent. Due to reorientation of the PN2 subdomain in the
tight monomer, a hydrophobic pocket at the interface of
PN2 and PC1 subdomains is created (Figure 2). This
pocket is situated close to the end of tunnels 1 and 2 in
the tight conformer (defined by the PN1 subdomain of
the adjacent open monomer) and is rich in aromatic
amino acids (Bohnert et al., 2008), a feature that is often
observed for binding pockets of MDR proteins (Zhelez-
nova et al., 1999; Schumacher et al., 2001, 2004; Murray
et al., 2004; see Figure 2, inset). Indeed, Murakami et al.
(2006) detected electron densities for the AcrB sub-
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Figure 3 Schematic representation of the AcrB binding change
functional rotation transport mechanism.
The conformational states loose (L), tight (T) and open (O) are
indicated in different levels of gray. The lateral grooves in the L
and T monomer indicate the substrate binding sites. The differ-
ent geometric forms reflect low (triangle), high (rectangle) or no
(circle) binding affinity for the transported substrates. State TTT
is postulated to occur at high substrate concentration. The
states LLL and LLT are postulated to occur in the absence or at
low substrate concentrations. In this model, bi-site activation is
essential for the complete transport cycle wadapted from Pos
(2009) and modifiedx.
strates minocycline and doxorubicin in the hydrophobic
pocket. By using a brominated derivative of the former
compound (9-bromo-minocyclin), they unambiguously
could assign the position of this substrate within the
binding pocket. In the open monomer, the lateral peri-
plasmic entrance of the tunnel observed in the loose and
tight conformation is now closed owing to coil-to-helix
transition of TM8, whereas another tunnel (tunnel 3) is
created due to tilting of the pore helix (PN1 subdomain).
The latter tunnel leads from the now collapsed binding
pocket to the funnel located in the center of the AcrB
trimer (Figure 2).
Transport mechanism
It is postulated (Murakami et al., 2006; Seeger et al.,
2006, 2008b; Sennhauser et al., 2007; Murakami, 2008;
Pos, 2009) that substrate transport by AcrB is accom-
plished via functional rotation in which each monomer
changes its conformation in a concerted fashion (Figure
3). The mechanism resembles that of Boyer’s binding
change mechanism of the F1Fo ATPase, where confor-
mational cycling of the (a and) b subunits through the
states loose, tight and open leads to the synthesis of ATP
(Hackney et al., 1979; Hutton and Boyer, 1979; Boyer,
1997).
One transport hypothesis assumes the substrates to
be garnered from the outer leaflet of the inner membrane
(Figure 2). Substrate might enter the loose monomer via
the TM8/TM9 groove (Murakami et al., 2002; Seeger et
al., 2008a; Pos, 2009) or via tunnel 2 approximately 15 A˚
above the membrane plane. While it is not clear how
hydrophobic compounds might enter tunnel 2 once these
have been partitioned in the inner membrane, several
groups provided structural data of symmetric AcrB
(where all the monomers adopt the loose conformation)
based on 3.2–3.8 A˚ data with presumably bound AcrB
substrates in the tunnel 2 region (Yu et al., 2005; Drew
et al., 2008). High resolution (2.5 A˚) data describing the
asymmetric trimer show clear densities in the TM8/TM9
groove of the loose monomer, which has been attributed
to the highly concentrated detergent and AcrB substrate
n-dodecyl-b-D-maltoside (Sennhauser et al., 2007). Upon
conformational change from the loose to the tight state,
tunnel 1 appears and might provide one of the pathways
for substrates towards the hydrophobic pocket which
accommodates the substrate molecule. Structural flexi-
bility within the trimer (Takatsuka and Nikaido, 2007;
Seeger et al., 2008b) suggests that the loose and even
tight conformational states might be adoptable in the
absence of substrates and that substrate binding to the
hydrophobic pocket specifically stabilizes the tight con-
formation. This might also present an alternative role for
tunnel 2 in these conformations as an exit pathway for
compounds which are not substrates of the pump (Figure
2). In analogy with the binding change mechanism (Mil-
grom et al., 1998), the conversion of the tight monomer
to the open monomer is energy-consuming and subject
to bi-site activation, i.e., only occurs upon binding of
substrate to the neighboring monomer (Figure 3). Upon
transition from the tight to the open state, the binding
pocket closes again; substrate is squeezed out and fol-
lows a newly formed tunnel (tunnel 3) to the TolC-docking
domain funnel, and is from there finally extruded into the
media via TolC.
In summary, upon conformational change from loose
to tight to open and back to loose, an alternating access
tunnel is formed through which substrates are transport-
ed from the outer leaflet of the inner membrane towards
the outside medium. The mode of action is suggested to
be based on occlusions migrating from the lateral
entrance(s) to the central funnel and is reminiscent of a
peristaltic pump.
To test the proposed conformational cycling in vivo,
subdomains that undergo substantial rearrangement dur-
ing cycling were locked by the introduction of disulfide
bonds (Takatsuka and Nikaido, 2007; Seeger et al.,
2008b). As could be demonstrated by tracing the efflux
of a fluorescent substrate, formation of disulfide bonds
significantly decreased AcrB mediated transport. When
the disulfide bonds were broken by the addition of the
reducing reagent dithiothreitol, transport activity was
restored, which was in strong support of the functional
rotation mechanism. Even more convincing, Takatsuka
and Nikaido designed a functional covalently linked AcrB
trimer, which could be inactivated by the introduction of
a mutation in the proton relay network (D407A) or by
disulfide formation in only one of the protomers (Takat-
suka and Nikaido, 2009). These results are in accordance
with the proposed functional rotation mechanism. More-
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over, using quantitative measurements with b-lactams as
substrates, Nagano and Nikaido (2009) found positive
cooperativity for cephalosporins with low apparent affin-
ity to AcrB (but not for nitrocefin, a cephalosporin with
high affinity), which might indicate bi-site activation as
postulated (Seeger et al., 2008a; Pos, 2009).
The interaction between each AcrB monomer and its
affiliated AcrA molecule has been investigated very
recently (Symmons et al., 2009) and might suggest that
during functional rotation of AcrB subtle conformational
changes are transmitted towards AcrA. Rather than just
being a rigid adapter, AcrA might actively transduce ener-
gy generated by AcrB and induce subtle peristaltic
motions in the TolC channel. Similar to the tunnels
observed in a single AcrB protomer during functional
rotation (Murakami et al., 2006; Seeger et al., 2006;
Sennhauser et al., 2007), TolC is possibly not a rigid hol-
low cylinder but changes its diameter by conformational
change of each monomer, thereby pushing substrate
unidirectionally from the closing aperture into the media
(Vaccaro et al., 2006, 2008; Seeger et al., 2008a; Pos,
2009).
Proton transport and energy transduction
AcrB utilizes the proton motive force to energize the
extrusion of its cognate substrates from the cell into the
medium (Zgurskaya and Nikaido, 1999; Saier and Paul-
sen, 2001). The TM domain of AcrB harbors four func-
tionally essential charged residues that are conserved
throughout the HAE-1 family: Asp407, Asp408, Lys940
and Arg971 (Su et al., 2006; Takatsuka and Nikaido,
2006). Another highly conserved TM residue, Thr978, is
in hydrogen bonding distance from Asp407 in the loose
and tight monomer and with Lys940 in the open mono-
mer. However, when Thr978 was replaced by valine,
isoleucine, leucine or asparagine, the relative activity of
these mutants remained 40% to 60% as revealed by
drug susceptibility assays (Takatsuka and Nikaido, 2006).
In the asymmetric structure of AcrB, the four above-
mentioned essential residues Asp407, Asp408, Lys940
and Arg971 have distinct different conformations in at
least one of the three conformers loose, tight and open
(Murakami et al., 2006; Seeger et al., 2006; Sennhauser
et al., 2007). Both structural and mutagenesis studies
suggest that proton translocation is mediated by these
titratable residues. The conformational changes during
the putative conformational cycling in the TM domain are
much more subtle compared to the porter domain:
Lys940 is sandwiched between Asp407 and Asp408 in
the loose and tight states, but becomes reoriented
towards Thr978 in the open state; the N-terminal end of
TM8 in the loose and tight monomers is marked by
Pro874, but becomes elongated by four full turns in the
open monomer, whereas TM5 bulges towards TM4 and
TM10 in the open conformation. These conformational
changes are thought to be the result of protonation and
deprotonation events on these titratable, membrane
embedded residues. The geometry of the titratable resi-
dues is reminiscent to the situation observed in bacterio-
rhodopsin, an archaeal integral membrane protein
intensively studied since its discovery in the early sev-
enties (Oesterhelt and Stoeckenius, 1973). It is therefore
tempting to look for analogies between AcrB and the
well-characterized bacteriorhodopsin. How these confor-
mational changes are levered to the porter domain and
cause the large conformational changes observed there
is subject to ongoing investigation.
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